نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

biogen nz biopharma ltd - interferon beta-1a 60 µg/ml - solution for injection - 30 mcg/0.5ml - active: interferon beta-1a 60 µg/ml excipient: arginine hydrochloride glacial acetic acid polysorbate 20 sodium acetate trihydrate water for injection - indicated for the treatment of relapsing forms of multiple sclerosis (ms).

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

biogen nz biopharma ltd - interferon beta-1a 60 µg/ml - solution for injection - 30 mcg/0.5ml - active: interferon beta-1a 60 µg/ml excipient: arginine hydrochloride glacial acetic acid polysorbate 20 sodium acetate trihydrate water for injection - indicated for the treatment of relapsing forms of multiple sclerosis (ms).

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

merck europe b.v.  - interferon beta-1a - multiple sclerosis - immunostimulants, - rebif is indicated for the treatment of:patients with a single demyelinating event with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing multiple sclerosis. in clinical trials, this was characterised by two or more acute exacerbations in the previous two years.efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity.

كندا - الإنجليزية - Health Canada

biogen canada inc - peginterferon beta-1a - liquid - 63mcg - peginterferon beta-1a 63mcg - interferons

كندا - الإنجليزية - Health Canada

biogen canada inc - peginterferon beta-1a - liquid - 94mcg - peginterferon beta-1a 94mcg - interferons

كندا - الإنجليزية - Health Canada

biogen canada inc - peginterferon beta-1a - liquid - 125mcg - peginterferon beta-1a 125mcg - interferons

كندا - الإنجليزية - Health Canada

biogen canada inc - peginterferon beta-1a; peginterferon beta-1a - kit - 63mcg; 94mcg - peginterferon beta-1a 63mcg; peginterferon beta-1a 94mcg - interferons

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

biogen netherlands b.v.  - interferon beta-1a - multiple sclerosis - immunostimulants, - avonex is indicated for the treatment of:patients diagnosed with relapsing multiple sclerosis (ms). in clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; avonex slows the progression of disability and decreases the frequency of relapses;patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite ms.avonex should be discontinued in patients who develop progressive ms.

كندا - الإنجليزية - Health Canada

emd serono, a division of emd inc., canada - interferon beta-1a; interferon beta-1a - kit - 8.8mcg; 22mcg - interferon beta-1a 8.8mcg; interferon beta-1a 22mcg - immunomodulatory agents

كندا - الإنجليزية - Health Canada

emd serono, a division of emd inc., canada - interferon beta-1a - solution - 22mcg - interferon beta-1a 22mcg - immunomodulatory agents